Article Figures & Data
Figures
- Figure 1.
Experiment 1 training data. Percent time freezing to the CS during the PTC phase are presented in the upper panel for each group. Mean avoidance shuttle responses from the USAA phase are presented in the middle panel for three-session blocks of training for each group. Freezing data to the USAA context for the first 5 min of sample sessions (1, 5, 10, and 15) are presented in the lower panel for each group in terms of percent time.
- Figure 2.
Experiment 1 test data. A, Experimental design, IP stands for intraperitoneal propranolol, procaterol or vehicle treatments administered before tests. B, Shuttling data during the PIT testing phase. These data are presented in terms of responses per minute for each group. Asterisks refer to statistical significance between the pre and CS periods while the hash indicates significance between vehicle and propranolol-treated subjects during the CS (all at the 0.05 α level). C, Freezing during the CS presentations in the PIT testing phase are presented in terms of percent time. The asterisk denotes significant differences in freezing between propranolol and procaterol-treated subjects. D, Freezing during the CS in the follow-up test for CS-elicited freezing conducted in the nonavoidance context. The asterisk signifies statistically significant differences in freezing between procaterol-treated subjects and all other groups.
- Figure 3.
Experiment 2. A, Design for experiment 2 training and transfer tests. B, Data from PIT tests preceded by IP and intracranial CNO/vehicle treatments are presented as a function of drug in terms of responses per minute during the pre and CS intervals. C, Data from control subjects that received IP CNO treatment before PIT testing but were not expressing hM3Dq receptors are also presented in terms of responses per minute. D, Postoperative PIT test data from subjects treated with intracranial vehicle and CNO before sessions without hM3Dq expression. E, The data from the follow-up tests for CS-elicited freezing are presented in terms of percent time freezing and are also expressed as a function of presession drug treatment. Asterisks indicate significance at the 0.05 α level.
- Figure 4.
Experiment 2 histology. A, Minimum (red) and maximum (green) viral expression in LC. Values are mm relative to the interaural line. B, Viral expression in LC (HA-tag, red), DBH staining (green), and a merge of the two (yellow; scale bar = 500 μm). C, Infusion sites for intracranial CNO treatment are presented relative to bregma (mm). D, Axon terminal expression of DREADD in CeA (HA-tag, red; scale bars = 500 μm (lower magnification) and 100 μm (higher magnification). HA-immunostaining in CeA is indicated by white arrows.
In this issue
